Skip to main content
HairCited

Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial.

Young Hye Cho, Sang Yeoup Lee, Dong Wook Jeong, Eun Jung Choi, Yun Jin Kim et al.
Other Evidence-based complementary and alternative medicine : eCAM 2014 86 citazioni
PubMed DOI PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D24864154'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo di studio
Randomized Controlled Trial
Dimensione del campione
76
Durata
24 weeks
Intervento
Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. 400 mg/day
Comparatore
Placebo
Direzione dell'effetto
Positive
Rischio di bias
Low

Abstract

Pumpkin seed oil (PSO) has been shown to block the action of 5-alpha reductase and to have antiandrogenic effects on rats. This randomized, placebo-controlled, double-blind study was designed to investigate the efficacy and tolerability of PSO for treatment of hair growth in male patients with mild to moderate androgenetic alopecia (AGA). 76 male patients with AGA received 400 mg of PSO per day or a placebo for 24 weeks. Change over time in scalp hair growth was evaluated by four outcomes: assessment of standardized clinical photographs by a blinded investigator; patient self-assessment scores; scalp hair thickness; and scalp hair counts. Reports of adverse events were collected throughout the study. After 24 weeks of treatment, self-rated improvement score and self-rated satisfaction scores in the PSO-treated group were higher than in the placebo group (P = 0.013, 0.003). The PSO-treated group had more hair after treatment than at baseline, compared to the placebo group (P < 0.001). Mean hair count increases of 40% were observed in PSO-treated men at 24 weeks, whereas increases of 10% were observed in placebo-treated men (P < 0.001). Adverse effects were not different in the two groups.

Full Text

PDF
Loading PDF...

Figures

Tables

Table 1

Treatment (N = 37)Placebo (N = 39) P value*
Age (years)45.6 ± 9.946.8 ± 10.30.615
Age of onset of hair loss (years)34.2 ± 8.636.8 ± 9.80.223
The Norwood-Hamilton grade0.373
Stage 28 (21.6)4 (10.3)
Stage 35 (13.5)2 (5.1)
Stage 3V11 (29.7)15 (38.5)
Stage 47 (18.9)8 (20.5)
Stage 5 6 (16.2)10 (25.6)
Family history of androgenetic alopecia27 (73.0)27 (69.2)0.719
Smoking (pack-year)5.9 ± 8.82.6 ± 6.40.067
Body mass index (kg/m2)24.7 ± 2.924.5 ± 2.90.734

Table 2

VariablesTreatment (N = 37)Placebo (N = 39) P value* P value
Week 0 Week 24Δ 24−0 weeksWeek 0 Week 24Δ 24−0 weeks
Body weight (kg)72.9 ± 10.172.4 ± 10.2−0.5 ± 1.671.1 ± 10.671.0 ± 10.80.1 ± 2.30.079, 0.7470.419
WC (cm)89.0 ± 7.385.8 ± 6.7−3.3 ± 3.687.1 ± 6.183.7 ± 6.5−3.4 ± 6.1 0.000, 0.001 0.890
Systolic BP (mmHg)125.6 ± 15.5124.4 ± 13.8−1.2 ± 11.3128.3 ± 14.6129.3 ± 13.81.0 ± 15.80.518, 0.7100.496
Diastolic BP (mmHg)84.1 ± 12.884.0 ± 10.7−0.1 ± 10.085.9 ± 13.685.2 ± 10.7−0.8 ± 13.90.948, 0.7310.813
Fasting glucose (mg/dL)109.9 ± 30.0112.9 ± 14.93.1 ± 27.2104.4 ± 16.4114.5 ± 22.410.1 ± 23.40.499, 0.011 0.229
AST (IU/L)22.0 ± 3.922.9 ± 4.60.9 ± 4.722.7 ± 4.125.7 ± 6.43.0 ± 5.80.246, 0.002 0.091
ALT (IU/L)20.3 ± 8.522.7 ± 11.62.3 ± 10.423.5 ± 8.727.2 ± 13.33.6 ± 11.10.183, 0.049 0.603
GGT (IU/L)33.0 ± 29.731.4 ± 17.6−1.6 ± 18.538.5 ± 25.340.3 ± 27.41.8 ± 12.60.603, 0.3780.351
Creatinine (mg/dL)0.92 ± 0.130.91 ± 0.14−0.01 ± 0.080.96 ± 0.130.96 ± 0.14−0.00 ± 0.110.290, 0.8270.658
Free testosterone (pg/mL)8.5 ± 3.29.5 ± 3.10.9 ± 3.710.9 ± 3.610.2 ± 3.4−0.7 ± 3.50.135, 0.2350.055

Table 3

Treatment (N = 37)Placebo (N = 39) P value*
12 weeks24 weeks12 weeks24 weeksWeeks 12 and 24
Self-improvement1 2.9 ± 2.53.4 ± 2.72.5 ± 2.82.1 ± 2.00.514, 0.013
Self-satisfaction1 3.4 ± 2.93.5 ± 2.92.6 ± 2.62.3 ± 2.00.214, 0.003

Table 4

Treatment (N = 37)Placebo (N = 39) P value
Week 0Week 24Week 0Week 24Weeks 0 and 24
SBP ≥ 140 or DBP ≥ 90 mmHg*13 (35.1)13 (33.3)12 (32.4)13 (33.3)0.764, 0.933
Fasting glucose ≥ 126 mg/dL* 6 (16.2) 8 (21.6) 5 (12.8)10 (25.6)0.674, 0.680
AST or ALT ≥ 1.5 × upper limit of normal**0 (0.0)1 (2.7)0 (0.0) 2 (5.1)NA, 0.520
Creatinine ≥ 1.5 mg/dL**0 (0.0)1 (2.7)0 (0.0)0 (0.0)NA, 0.487

References

  1. Untitled
  2. Untitled
  3. Untitled
  4. Untitled
  5. Untitled
  6. Untitled
  7. Untitled
  8. Untitled
  9. Untitled
  10. Untitled
  11. Untitled
  12. Untitled
  13. Untitled
  14. Untitled
  15. Untitled
  16. Untitled
  17. Untitled
  18. Untitled
  19. Untitled
  20. Untitled
  21. Untitled
  22. Untitled
  23. Untitled
  24. Untitled
  25. Untitled
  26. Untitled

Used In Evidence Reviews

Similar Papers